KBKristin L. Bigos

Kristin L. Bigos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kristin L. Bigos has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Sex differences in the pharmacokinetics and pharmacodynamics of antidepressants: An updated review

    by Kristin L. Bigos, Bruce G. Pollock, Beth A. Stankevich, Robert R. Bies


  • Dysregulation of neurosteroids in obsessive compulsive disorder

    by K.L. Bigos, M.M. Folan, M.R. Jones, G.L. Haas, F.J. Kroboth, P.D. Kroboth


  • Open Access

    Acute 5-HT Reuptake Blockade Potentiates Human Amygdala Reactivity

    by Kristin L Bigos, Bruce G Pollock, Howard J Aizenstein, Patrick M Fisher, Robert R Bies, Ahmad R Hariri

    Variability in serotonin (5-HT) function is associated with individual differences in normal mood and temperament, as well as psychiatric illnesses, all of which are influenced by amygdala function. This study evaluated the acute effects of 5-HT reuptake blockade on amygdala function using pharmacological functional MRI. Eight healthy men completed a double-blind balanced crossover study with the selective 5-HT reuptake inhibitor, citalopram (20 mg infused over 30 min), and normal saline. Amygdala reactivity in response to novel facial expressions was assessed on three successive scans, once before drug/placebo infusion, once early in the infusion, and once at the end of infusion. Acute citalopram administration resulted in concentration-dependent increases in human amygdala reactivity to salient stimuli. The current pattern of 5-HT-mediated amygdala reactivity may represent an important pathway through which SSRIs achieve an antidepressant effect. Intriguingly, our data may also reveal a mechanism contributing to clinical observations of extreme agitation, restlessness, and suicidal ideation in some individuals during acute SSRI treatment. Developing a comprehensive model of how 5-HT modulates human amygdala reactivity supporting behavioral and physiological arousal will be instrumental for our understanding of basic neurobehavioral processes, their dysfunction in psychiatric illnesses, and their contribution to mechanism of treatment response.


    • 1 January 2003
      • Vol. 6  (3) , 12-20

    Gender differences in the pharmacokinetics and pharmacodynamics of antidepressants.

    by Robert R Bies, Kristin L Bigos, Bruce G Pollock

    The paucity of research on gender-specific differences related to antidepressants is a significant public health deficiency and represents an understudied and necessary research area. The current data suggest that the pharmacokinetics of antidepressant drugs can be substantially different between men and women as a result of differences in both the metabolizing enzymes and the expression of P-glycoprotein MDR1. The data suggest that different pharmacodynamic responses are observed between premenopausal women and men. Women are more likely to respond better to an MAOI antidepressant compared to men. In addition, men respond better to TCAs than women in this age group, but differences diminish after menopause. Given the evidence of distinct gender-specific differences, it is critical that these differences be addressed more widely in research evaluating the administration of antidepressants in women.